Le Lézard
Classified in: Covid-19 virus

Global Inhaled and Intranasal Products 2020-2030: Contract Service Providers Market - Focus on Drugs and Drug Delivery Systems - ResearchAndMarkets.com


The "Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The 'Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 - 2030' report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain.

Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases/disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide).

As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and/or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRAT (migraine), NUMBRINOT (local anesthetic), GIMOTIT (diabetic gastroparesis), VALTOCO (epilepsy), NAYZILAM (epilepsy), DUAKLIR PRESSAIR (COPD), PROAIR DIGIHALERT (asthma and COPD), AIRDUO DIGIHALERT (asthma), SPRAVATO (depression).

Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges. Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target.

These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion/thickening, narrowing/collapse of airways, fibrosis and poor blood circulation. In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine.

Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development.

Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial growth in the coming years.

Key Questions Answered

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Historical Evolution of Inhaled and Intranasal Therapy

3.3. Types of Inhalable and Intranasal Drug Formulations

3.4. Types of Inhalable and Intranasal Drug Delivery Systems Formulations

3.4.1. Pressurized Metered Dose Inhalers

3.4.2. Dry Powder Inhalers

3.4.3. Nebulizers

3.4.4. Metered Spray Pumps / Intranasal Sprays

3.4.5. Aqueous Droplet Inhalers

3.5. Assessment of Quality and Performance During Inhalable and Intranasal Drug Development

3.6. Regulatory Landscape

3.7. Approved Inhaled and Intranasal Therapeutics Available in Developed Markets (the US and UK)

3.8. Importance of Outsourcing Inhaled and v Product Development Operations

3.9. Future Perspectives

4. INHALED AND INTRANASAL DRUG PRODUCT SERVICE PROVIDERS: MARKET LANDSCAPE

4.1. Chapter Overview

4.2. Inhaled and Intranasal Drug Product Service Providers: Overall Market Landscape

4.2.1. Analysis by Year of Establishment

4.2.2. Analysis by Company Size

4.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size

4.2.4. Analysis by Type of Service Provider

4.2.5. Analysis by Company Size and Type of Service Provider

4.2.6. Analysis by Scale of Operation

4.2.7. Analysis by Location of Headquarters

4.2.8. Heat Map: Analysis by Company Size and Location of Headquarters

4.2.9. World Map: Analysis by Inhaled and Intranasal Drug Product Manufacturing Facilities

4.2.10. Analysis by Type of Drug Molecule

4.2.11. Analysis by Type of Inhaled and Intranasal Drug Product Related Primary Service(s) Offered

4.2.12. Analysis by Type of Inhaled and Intranasal Drug Product Related Secondary Service(s) Offered

4.2.13. Analysis by Type of Formulation

4.2.14. Analysis by Type of Dosage Form

4.2.15. Analysis by Route of Administration

4.2.16. Information on Production Capacity

5. INHALED AND INTRANASAL DRUG DELIVERY SYSTEM MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

5.1. Chapter Overview

5.2. Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Overall Market Landscape

5.2.1. Analysis by Year of Establishment

5.2.2. Analysis by Company Size

5.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size

5.2.4. Analysis by Scale of Operation

5.2.5. Analysis by Location of Headquarters

5.2.6. Analysis by Location of Inhaled and Intranasal Drug Delivery System Manufacturing Facilities

5.2.7. Analysis by Type of Inhaled and Intranasal Drug Delivery System Manufacturing Service(s) Offered

5.2.8. Analysis by Type of Formulation

5.2.10. Analysis by Type of Drug Delivery Systems

6. COMPANY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview

6.2. Methodology and Key Parameters

6.3. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers

6.4. Inhaled and Intranasal Drug Product Contract Research Service Providers

6.5. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers

7. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN NORTH AMERICA

7.1. Chapter Overview

7.2. Capsugel

7.2.1. Recent Developments and Future Outlook

7.3. Catalent

7.4. DPT Laboratories (A Mylan Company)

7.5. Kindeva Drug Delivery (Formerly 3M Drug Delivery Systems)

8. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC

8.1. Chapter Overview

8.2. Beximco Pharmaceuticals

8.2.1. Recent Developments and Future Outlook

8.3. Colep

8.4. Hovione

8.5. Orion

8.6. Quotient Sciences

8.7. Recipharm

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview

9.2. Partnership Models

9.3. Inhaled and Intranasal Contract Research and Manufacturing Service Providers:

9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership

9.3.3. Analysis by Scale of Operation

9.3.4. Analysis by Type of Inhaled and Intranasal Drug Product Related Service(s) Offered

9.3.5. Analysis by Type of Formulation

9.3.6. Analysis by Type of Drug Delivery Systems Used

9.3.7. Most Active Players: Analysis by Number of Partnerships

10. MAKE VERSUS BUY DECISION MAKING

10.1. Chapter Overview

10.2. Assumptions and Parameter Definitions

10.3. Concluding Remarks

11. DEMAND ANALYSIS

11.1. Chapter Overview

11.2. Assumptions and Methodology

11.3. Global Demand for Inhaled and Intranasal Drug Delivery Systems, 2020-2030

11.3.1. Analysis by Route of Administration

11.3.2. Analysis by Type of Drug Delivery Systems Used

11.3.3. Analysis by Geographical Location

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1. Chapter Overview

12.2. Forecast Methodology and Key Assumptions

12.3. Overall Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030

12.4. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations, 2020-2030

12.5. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations, 2020-2030

12.6. Overall Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030

13. IMPACT OF COVID-19 PANDEMIC ON THE INHALED AND INTRANASAL SERVICE PROVIDERS MARKET

13.1 Chapter Overview

13.2. Current Opinions and Recuperative Initiatives of Key Players

13.2.1. Catalent

13.2.2. Hovione

13.2.3. Lonza

13.2.4. Quotient Sciences

13.2.5. Recipharm

13.3. Impact on Inhaled and Intranasal Product Service Providers Market

13.4. Recuperative Strategies for Contract Service Providers

13.4.1. Strategies for Implementation in the Short / Mid Term

13.4.2. Strategies for Implementation in the Long Term

14. CONCLUSION

14.1. Chapter Overview

15. EXECUTIVE INSIGHTS

15.1. Chapter Overview

15.2. King's College London

15.2.1. Organization Snapshot

15.2.2. Interview Transcript: Ben Forbes, Professor

15.3. Nelson Laboratories

15.3.1. Company Snapshot

15.3.2. Interview Transcript: Dries Cardoen, Team Leader of Study Directors

15.4. The Indian Pharmaceutical Association

15.4.1. Company Snapshot

15.4.2. Interview Transcript: Neeraj Kumar, Honorary Secretary

16. APPENDIX 1: TABULATED DATA

For more information about this report visit https://www.researchandmarkets.com/r/4i9ls6


These press releases may also interest you

at 18:00
The "Prepaid Cards - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Prepaid Cards estimated at US$2 Trillion in the year 2023, is projected to reach a revised size of US$4.1 Trillion by...

at 17:25
Five years after the transformational Merger with Randgold Resources, Barrick Gold Corporation has been restructured and repurposed as a modern mining business with a constantly replenished, global asset base of peerless quality, managed by a team...

at 17:15
The "Australia Plastic Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to  ResearchAndMarkets.com's offering. The Australia Plastic Packaging Market size estimated at USD 2.79...

at 17:05
Trinity Capital Inc.  ("Trinity" or the "Company"), a leading provider of diversified financial solutions to growth stage companies, today announced an adjustment to the conversion rate of its 6.00% Convertible Notes due 2025 (the "Convertible...

at 16:40
Vista Outdoor Inc. ("Vista Outdoor", "we", "us" or "our") and Czechoslovak Group a.s. ("CSG") announced today that they have voluntarily withdrawn and re-filed their joint voluntary notice to the Committee on Foreign Investment in the United States...

at 16:35
The Board of Directors of Chimera Investment Corporation announced the declaration of its first quarter cash dividend of $0.11 per common share. The dividend is payable April 30, 2024 to common stockholders of record on April 8, 2024. The ex-dividend...



News published on and distributed by: